Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis

Abstract

Glucocorticoids (GCs) are potent immune‐modulating drugs with significant side effects, including glucocorticoid‐induced osteoporosis (GIO). GCs directly induce osteoblast and osteocyte apoptosis but also alter intestinal microbiota composition. Although the gut microbiota is known to contribute to the regulation of bone density, its role in GIO has never been examined. To test this, male C57/Bl6J mice were treated for 8 weeks with GC (prednisolone, GC‐Tx) in the presence or absence of broad‐spectrum antibiotic treatment (ABX) to deplete the microbiota. Long‐term ABX prevented GC‐Tx‐induced trabecular bone loss, showing the requirement of gut microbiota for GIO. Treatment of GC‐Tx mice with a probiotic (Lactobacillus reuteri [LR]) prevented trabecular bone loss. Microbiota analyses indicated that GC‐Tx changed the abundance of Verrucomicobiales and Bacteriodales phyla and random forest analyses indicated significant differences in abundance of Porphyromonadaceae and Clostridiales operational taxonomic units (OTUs) between groups. Furthermore, transplantation of GC‐Tx mouse fecal material into recipient naïve, untreated WT mice caused bone loss, supporting a functional role for microbiota in GIO. We also report that GC caused intestinal barrier breaks, as evidenced by increased serum endotoxin level (2.4‐fold), that were prevented by LR and ABX treatments. Enhancement of barrier function with a mucus supplement prevented both GC‐Tx–induced barrier leakage and trabecular GIO. In bone, treatment with ABX, LR or a mucus supplement reduced GC‐Tx–induced osteoblast and osteocyte apoptosis. GC‐Tx suppression of Wnt10b in bone was restored by the LR and high‐molecular‐weight polymer (MDY) treatments as well as microbiota depletion. Finally, we identified that bone‐specific Wnt10b overexpression prevented GIO. Taken together, our data highlight the previously unappreciated involvement of the gut microbiota and intestinal barrier function in trabecular GIO pathogenesis (including Wnt10b suppression and osteoblast and osteocyte apoptosis) and identify the gut as a novel therapeutic target for preventing GIO. © 2019 American Society for Bone and Mineral Research.

Skeletal Protection and Promotion of Microbiome Diversity by Dietary Boosting of the Endogenous Antioxidant Response

“…An association between gut microbiome and skeletal changes has been shown to involve leakage of the intestinal blood barrier and increased circulating endotoxin in estrogen deficiency, glucocorticoid excess, and parathyroid hormone–induced bone anabolism. ( 56–58 ) Whether the intestinal barrier is affected in mice fed the Mont diet is the subject of current studies and would support a connection between activation of anti‐inflammatory pathways and nutrition. Future studies in humans are warranted to examine the effectiveness of blueberry diets on the skeleton, the linkage with microbiome diversity, as well as the sexual dimorphism found in mice in the current study.…”

Gut Microbiota Status in COVID-19: An Unrecognized Player?

“…To this regard, two recent studies reported that glucocorticoids induce gut microbial alterations in mice. (Schepper et al, 2019) and humans (Qiu et al, 2019). In human subjects diagnosed for acute transverse myelitis, 3 months treatment with prednisone promoted enrichment in Firmicutes and depletion in Bacteroidetes (Qiu et al, 2019).…”

Gut microbial-derived short-chain fatty acids and bone: a potential role in fracture healing

“…Animal models indicate that the absence of a gut microbiota leads to changes in bone remodelling, trabecular bone mineral density and bone volume fraction (Sjogren et al, 2012;Yan and Charles, 2017). Modifications to the gut microbiota have also been shown to reduce bone loss caused by oestrogen depletion (Britton et al, 2014; or glucocorticoid treatment (Schepper et al, 2020), two of the most common contributors to osteoporosis (Marcus, 2013). Changes in the gut microbiome can also mediate the effects of osteoporosis therapies such as the use of PTH (Li et al, 2020;Yu et al, 2020).…”